Skip to main content

HIV protease inhibitor resistance by enzyme-substrate coevolution

Objective

Despite the success of antiretroviral drugs, therapy of HIV/AIDS still suffers from severe drawbacks because of undesired consequences of therapy. The major undesired consequence is resistance which renders individual drugs and complete drug classes ineffective. 70-80% of HIV-infected patients undergoing resistance testing carry drug resistant virus and 10% of new transmissions involve resistant or multi-resistant viruses. With the roll out of HIV therapy in developing countries, drug resistance will become a worldwide problem, while resistance development in non-subtype B strains of HIV (dominant in developing countries) is largely inferred from results obtained with subtype B viruses. Protease inhibitors (PI) have been a key factor in the success of HIV therapy, but as with all clinically used drugs resistance has been observed.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Coordinator

UNIVERSITÄTSKLINIKUM HEIDELBERG
Address
Im Neuenheimer Feld 672
Heidelberg
Germany

Participants (7)

BIOALLIANCE PHARMA SA
France
Address
59 Boulevard Du Général Martial Valin
Paris
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Germany
Address
Meyerhofstrasse 1
Heidelberg
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
France
Address
101, Rue De Tolbiac
Paris
INSTITUTE OF MOLECULAR GENETICS, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC
Czechia
Address
Flemingovo Nam, 2
Praha 6
INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC
Czechia
Address
Flemingovo Namesti 2
Praha-6
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
University Offices, Wellington Square
Oxford
UNIVERSITY MEDICAL CENTRE UTRECHT
Netherlands
Address
Heidelberglaan 100
Utrecht